TIGIT and glioblastoma: CRISPR-Cas9 is used to knockout immune checkpoint genes (e.g., PD-1, TIGIT, LAG-3) in T cells, enhancing their anti-tumor activity by overcoming immunosuppressive effects in the GBM microenvironment (Li X. et al., 2024).